Your browser doesn't support javascript.
loading
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.
Raubenheimer, Peter J; Cushman, William C; Avezum, Alvaro; Basile, Jan; Conget, Ignacio; Dagenais, Gilles; Hoover, Anastasia; Jansky, Petr; Lanas, Fernando; Leiter, Lawrence A; Lopez-Jaramillo, Patricio; Pogosova, Nana; Probstfield, Jeffrey; Rao-Melacini, Purnima; Rydén, Lars; Sheu, Wayne H-H; Temelkova-Kurktschiev, Theodora; C Gerstein, Hertzel.
Afiliación
  • Raubenheimer PJ; Division of Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Cushman WC; University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Avezum A; International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
  • Basile J; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Conget I; Endocrinology and Nutrition Department, Hospital Clínic, University of Barcelona, Barcelona, Spain.
  • Dagenais G; Institut Universitaire de Cardiologie et de Pneumologie de Québec. Université Laval Institute, Quebec City, Quebec, Canada.
  • Hoover A; Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Jansky P; University Hospital Motol, Prague, Czech Republic.
  • Lanas F; Universidad de La Fontera, Temuco, Chile.
  • Leiter LA; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Lopez-Jaramillo P; Masira Research Institute, Medical School, Universidad de Santander (UDES), Bucaramanga, Colombia.
  • Pogosova N; National Medical Research Center of Cardiology, Moscow, Russia.
  • Probstfield J; Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Rao-Melacini P; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Rydén L; Department of Medicine, Karolinska Institut, Stockholm, Sweden.
  • Sheu WH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Temelkova-Kurktschiev T; Robert Koch Medical Centre, Sofia, Bulgaria.
  • C Gerstein H; Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
Diabetes Obes Metab ; 24(4): 704-712, 2022 04.
Article en En | MEDLINE | ID: mdl-34984808
AIM: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in patients with type 2 diabetes treated with once-weekly subcutaneous dulaglutide versus placebo. MATERIALS AND METHODS: Patients without electrocardiographic (ECG)-confirmed AA at baseline and randomized in the REWIND trial were assessed for the development of AA based on an annual ECG. Additional analyses included whether dulaglutide compared with placebo reduced the composite outcome of AA or death, AA or cardiovascular death, AA or stroke and AA or heart failure. RESULTS: Among 9543 participants (mean age 66 ± 7 years, with cardiovascular risk factors and 31% with previous cardiovascular disease) without AA at entry in the trial, 524 patients (5.5%) had at least one episode of AA during the median 5.4 years of follow-up. Incident AA occurred in 269 of the 4769 participants allocated to dulaglutide (5.6%), at a rate of 10.7 per 1000 person-years, versus 255 of the 4774 allocated to placebo (5.3%), at a rate of 10.5 per 1000 person-years (P = .59). There was also no effect of dulaglutide on the composite outcome of AA and death or AA and heart failure. CONCLUSION: This post hoc analysis of data from the REWIND trial showed that treatment with dulaglutide was not associated with a reduced incidence of AA in this at-risk group of patients with type 2 diabetes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Sudáfrica Pais de publicación: Reino Unido